Pancreatic Cancer Screening in New-onset and Deteriorating Diabetes: Preliminary Results From the PANDOME Study - Takeaways - MDSpire

Pancreatic Cancer Screening in New-onset and Deteriorating Diabetes: Preliminary Results From the PANDOME Study

  • By

  • Richard C Frank

  • Brian Shim

  • Tammy Lo

  • Deep Pandya

  • Thorsten L Krebs

  • Charles Ma

  • Daniel Labow

  • Jill Denowitz

  • Naveen Anand

  • Pramila Krumholtz

  • Kiyoe Sullivan

  • Mark Sanchez

  • Xiang Eric Dong

  • Ramanathan Seshadri

  • Antolin Trinidad

  • Dugho Jin

  • May 29, 2025

  • 0 min

Share

  • 1

    The PANDOME trial focuses on screening for pancreatic cancer in individuals aged 50 and older with new-onset or deteriorating diabetes.

  • 2

    Among 109 enrolled participants, 97 had new-onset diabetes, while 12 had deteriorating diabetes, highlighting the trial's focus on high-risk groups.

  • 3

    The study identified one stage 1 pancreatic ductal adenocarcinoma in the deteriorating diabetes cohort, indicating a 0.9% detection rate.

  • 4

    Endocrinologists were the primary referral source for the deteriorating diabetes cohort, emphasizing their role in early detection.

  • 5

    The findings support including deteriorating diabetes patients in pancreatic cancer screening studies to improve early detection strategies.

Original Source(s)

Pancreatic Cancer Screening in New-onset and Deteriorating Diabetes: Preliminary Results From the PANDOME Study

  • by Richard C Frank, Brian Shim, Tammy Lo, Deep Pandya, Thorsten L Krebs, Charles Ma, Daniel Labow, Jill Denowitz, Naveen Anand, Pramila Krumholtz, Kiyoe Sullivan, Mark Sanchez, Xiang Eric Dong, Ramanathan Seshadri, Antolin Trinidad, Dugho Jin

  • May 29, 2025

Related Content

Reported Knowledge of Recent HbA1c, Blood Pressure, and LDL-cholesterol Levels and Goals Among US Adults with Diabetes—National Health and Nutrition Examination Survey 2011–2020

Sleep Program Shifted Teen Circadian Timing

Two-week chronotherapy trial evaluates circadian phase, sleep duration, and alignment outcomes.

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.